The founding and management team

Henrik is a pioneer and scientific leader in the field of proteomics-based drug discovery with over 20 years of industry experience commercializing cutting-edge proteomics technologies. Henrik joined NEOsphere Biotechnologies from Evotec, where he served as Senior Vice President Science & Technology. In that role, he developed high-throughput, deep proteomics on automated, industrial-scale platforms and led global target discovery efforts for targeted protein degradation. Prior to that, Henrik was a group leader at the Max Planck Institute of Biochemistry and scientific founder of the proteomics company Kinaxo Biotechnologies. Henrik has a PhD in biochemistry from the Max Planck Institute of Biochemistry and received his venia legendi from the Technical University of Munich, where he is also Professor of Biochemistry.

Jutta is an internationally accomplished expert in business development and strategic partnering within the life sciences and diagnostics industries. Her strong track record builds on nearly 20 years of management experience steering the organizational growth and long-term collaborations with pharmaceutical partners to successfully commercialize technologies. Prior to joining NEOsphere Biotechnologies, she was co-founder and CBO of the cancer diagnostics company NEO New Oncology (sold to Siemens Healthcare in 2016), VP Business Development for Proteomics Services at Evotec, and Head of Business Development at the proteomics company Kinaxo Biotechnologies (sold to Evotec in 2011). Jutta has a PhD in molecular biology from the University of Vienna and an MBA in financial management from the University of Wales.

Tanja is a business economist and expert in strategic and analytical business management. Her expertise builds on 15 years of management experience in international corporations such as Siemens and Nokia in the areas of strategic sourcing, global project management and consulting including financial management. In addition, she brings practical knowledge in the field of business start-up. Tanja holds a Diploma in Business Administration from the University of Applied Sciences in Munich, a degree from IPAG Business School in Nice and a Managing Director Certificate.

Martin has pioneered various state-of-the-art proteomics methods to validate target candidates of protein degraders. Those methods include the hypersensitive detection of degrader-induced ubiquitination events on neosubstrates using data-independent acquisition mass spectrometry (DIA-MS). Today, Martin spearheads the development of NEOsphere Biotechnologies’ high-throughput MS-based platforms. Martin has over 10 years of research experience. He worked on targeted protein degradation as a senior research scientist at Evotec and on MS-based proteomics with Prof. Matthias Mann at the Max Planck Institute of Biochemistry, where he discovered the first molecular marker for LRRK2, a gene often mutated in hereditary Parkinson's disease. Martin obtained his PhD in molecular cancer research from the University of Zurich.

Uli is a leading expert in industrial-scale, deep proteomic screening. He has over a decade of experience in mass spectrometry (MS)-based proteomics and broad expertise in laboratory automation and rapid scaling of proteomics infrastructure. Previously at Evotec, he was instrumental in the development of data-independent acquisition MS for single-shot proteomics with unprecedented throughput, depth, and sensitivity. Uli has a PhD in biochemistry from the University of Regensburg and was a postdoctoral researcher in the Mass Spectrometry Core Unit of Helmholtz Zentrum Munich.

Björn has been an expert in computational data analysis, statistical modelling, and data visualization for over a decade. In his previous position at Evotec, he developed complex software ecosystems to automate all aspects of handling, processing, and analyzing mass spectrometry data. Before that, he was a project leader in Computational Biology at the Max Planck Institute for Biophysical Chemistry, where he designed and evaluated high-throughput transcriptomics data analyses on high-performance computing clusters. Björn is a trained mathematician with a PhD in computational biology from the Ludwig-Maximilians-University in Munich and a degree in machine learning from Stanford University.